Jim Cramer knows what it looks like when stocks are drinking the Kool-Aid, and this ain't it.
The “Fast Money” weigh in on the biotech sector, as the iShares Nasdaq Biotechnology ETF IBB continues to surge.
The "Fast Money" traders discuss the trade on Gilead, which is down about 9 percent.
A judge rules Regeneron's cholesterol drug can stay on the market amid the company's ongoing patent case with Amgen. CNBC's Meg Tirrell reports.
Jim Cramer goes through his lightning round of callers, and weighs in on the state of oil ahead of the rig count.
The "Fast Money" traders run down their list of trades to make as U.S. markets rallied Friday.
The "Fast Money" traders digest Amazon's and Amgen's earnings reported after the bell on Thursday.
CNBC's Meg Tirrell reports on after-hours action for Amgen. The "Fast Money" traders weigh in.
The "Fast Money" traders give you 5 ways to trade 2 big earnings reports.
Stocks closed mostly flat as investors looked ahead to Friday's jobs report, amid growing tensions between the US and other global powers.
Earnings are out for Amgen. CNBC's Meg Tirrell reports the details.
Dan Loeb shares his views on the market, Trump and his fund's portfolio in a letter to clients.
U.S. stock index futures pointed to a lower open on Thursday as traders eyed a big day of earnings and digested economic data.
U.S. equities closed mostly higher on Wednesday after the Federal Reserve kept interest rates unchanged, as was widely expected.
Bank of America predicts Amgen shares could rally 23 percent in the next 12 months.
CNBC's Meg Tirrell reports on President Trump's meeting with big pharmaceutical CEOs, and how it is impacting the biotech sector. The "Fast Money" traders weigh in.
U.S. equities traded mixed as investors continued to evaluate the latest policies from the White House.
"We have to get the prices down," Trump tells drugmakers at the White House.
Stocks notched their worst day of 2017, as a new measure taken by the Trump administration on immigration sent jitters through the market.
Markets will be busy with economic reports and earnings, but Washington could continue to dominate.